PTJ
RGLS

Paul Tudor Jones’s Regulus Therapeutics RGLS Stock Holding History

Paul Tudor Jones’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-901
Closed -$178K – 1323
2017
Q1 		$178K Buy
901
+512
+132% +$97.5K 0.01% 1243
2016
Q4 		$105K Buy
+389
New +$126K ﹤0.01% 1300

Other funds holding RGLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SDIC
South Dakota Investment Council Sioux Falls, South Dakota $5.84B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Paul Tudor Jones's RGLS Position: Q2 2017 in Review

Paul Tudor Jones sold out of Regulus Therapeutics (RGLS) in Q2 2017, closing a stake of 901 shares — an estimated $178K sold.

Paul Tudor Jones first reported a position in RGLS in Q4 2016 and held it in 2 quarters. The position peaked at $178K in Q1 2017. 46 funds tracked by Wall St. Rank hold RGLS as of Q2 2017.

  • Paul Tudor Jones reported no remaining Regulus Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Paul Tudor Jones sold 901 Regulus Therapeutics shares in Q2 2017, an estimated $178K.
  • Paul Tudor Jones first reported a position in Regulus Therapeutics in Q4 2016 and held it in 2 quarters.
  • Paul Tudor Jones's Regulus Therapeutics position peaked at $178K in Q1 2017.
  • 46 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2017.

Based on Tudor Investment Corp's 13F filing for Q2 2017, filed 14 Aug 2017.